Stem Cell Theranostics, Inc.

Biotech · Defunct

In vitro screening platform using patient-derived iPSC cardiomyocytes to predict drug-induced cardiotoxicity

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$300K
Federal grants
$300K
2 awards · 2015–2017
Rank in peer group#39 of 42
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
2 pending

Capital timeline

201520162017FEDERAL ↑EQUITY ↓Cumulative $300K$150K$150K
201520162017FEDERAL ↑EQUITY ↓Cumulative $300K$150K$150K

Latest events

  • Federal grantHealth and Human S · Phase I · iCardioTox Profiler - Developing a Novel In Vitro Assay to Assess Cardiotoxicity Using a Panel of Patient-derived Cardiomyocytes$150K
  • Federal grantNSF · Phase I · SBIR Phase I: Developing a Novel In Vitro Assay Using Patient-derived Cardiomyocytes To Screen for Drugs To Treat Hypertrophic Cardiomyopathy$150K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 42 peers

Line = median

Biotech · Platform

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 2
  • PendingModulation Of Drug-induced CardiotoxicityUSPTOApplication PCTUS2016033652
  • PendingModulation Of Drug-induced CardiotoxicityUSPTOApplication 62165850
  • PROGENITOR INC.Similar federal contract value in Biotech · null in contracts
  • CELLECHO INCSimilar federal contract value in Biotech · null in contracts
  • EXHALIX, LLCSimilar federal contract value in Biotech · null in contracts
  • BIOTECERA INC.Similar federal contract value in Biotech · null in contracts
  • DRIVE THERAPEUTICS, L.L.C.Similar federal contract value in Biotech · null in contracts
  • Knudra DiagnosticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .